Why Neuren Pharmaceuticals (ASX:NEU) Is Up 6.3% After Record DAYBUE Royalties And Strong STIX Launch – And What's Next

Simply Wall St.05-12 03:30

In Q1 2026, Neuren Pharmaceuticals reported record net sales and more than 20% year-on-year royalty growth from Rett syndrome therapy DAYBUE, supported by Acadia Pharmaceuticals reaffirming full-year ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2634230366?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2026-05-12 03:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2634230366","market":"sg","top_or_hot":-1,"title":"Why Neuren Pharmaceuticals (ASX:NEU) Is Up 6.3% After Record DAYBUE Royalties And Strong STIX Launch – And What's Next","media":"Simply Wall St.","content":"<div>\n<p>In Q1 2026, Neuren Pharmaceuticals reported record net sales and more than 20% year-on-year royalty growth from Rett syndrome therapy DAYBUE, supported by Acadia Pharmaceuticals reaffirming full-year ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/why-neuren-pharmaceuticals-asxneu-is-up-63-after-record-dayb\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Neuren Pharmaceuticals (ASX:NEU) Is Up 6.3% After Record DAYBUE Royalties And Strong STIX Launch – And What's Next</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Neuren Pharmaceuticals (ASX:NEU) Is Up 6.3% After Record DAYBUE Royalties And Strong STIX Launch – And What's Next\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-12 03:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/why-neuren-pharmaceuticals-asxneu-is-up-63-after-record-dayb><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In Q1 2026, Neuren Pharmaceuticals reported record net sales and more than 20% year-on-year royalty growth from Rett syndrome therapy DAYBUE, supported by Acadia Pharmaceuticals reaffirming full-year ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/why-neuren-pharmaceuticals-asxneu-is-up-63-after-record-dayb\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NEU.AU","symbol_name":"NEUREN PHARMACEUTICALS LTD","start_time":0,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/why-neuren-pharmaceuticals-asxneu-is-up-63-after-record-dayb","article_id":"2634230366","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/why-neuren-pharmaceuticals-asxneu-is-up-63-after-record-dayb","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2634230366","pubTimestamp":1778527845,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In Q1 2026, Neuren Pharmaceuticals reported record net sales and more than 20% year-on-year royalty growth from Rett syndrome therapy DAYBUE, supported by Acadia Pharmaceuticals reaffirming full-year 2026 DAYBUE sales guidance of US$460–490 million.\nA key driver was the successful US launch of DAYBUE STIX, a new powder formulation that has seen strong uptake and high caregiver satisfaction, while clinical programs in regions such as Japan and Europe continue to progress.\nWe’ll now examine...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"NEU.AU":"NEUREN PHARMACEUTICALS LTD","BK4109":"特种化学制品","BK7508":"医药生物股","NEU":"NewMarket","BK7096":"制药"},"translate_title":"为什么Neuren Pharmaceuticals(ASX：NEU)在创纪录的DAYBUE特许权使用费和强劲的STIX推出后上涨6.3%-以及下一步是什么","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NEU.AU":1.5,"NEU":1.5},"content_text":"In Q1 2026, Neuren Pharmaceuticals reported record net sales and more than 20% year-on-year royalty growth from Rett syndrome therapy DAYBUE, supported by Acadia Pharmaceuticals reaffirming full-year 2026 DAYBUE sales guidance of US$460–490 million. A key driver was the successful US launch of DAYBUE STIX, a new powder formulation that has seen strong uptake and high caregiver satisfaction, while clinical programs in regions such as Japan and Europe continue to progress. We’ll now examine how DAYBUE STIX’s successful rollout and reinforced 2026 sales guidance may influence Neuren’s existing investment narrative. Outshine the giants: these 15 early-stage AI stocks could fund your retirement.AdvertisementNeuren Pharmaceuticals Investment Narrative RecapTo own Neuren today, you need to believe that DAYBUE can sustain meaningful uptake while the NNZ-2591 pipeline gradually broadens the revenue base beyond a single product and partner. In the near term, the key catalyst remains DAYBUE’s commercial performance, with the reaffirmed 2026 sales guidance and strong DAYBUE STIX uptake supporting that story. The biggest risk is still Neuren’s reliance on Acadia and DAYBUE royalties, and this update does not change that concentration risk in a material way. Among recent announcements, the ongoing on-market share buyback stands out in the context of these DAYBUE results. With Q1 2026 royalties growing more than 20% year on year and Acadia reiterating DAYBUE sales guidance of US$460–490 million, the buyback highlights how Neuren is choosing to allocate capital while royalty income builds. For investors focused on near term catalysts, the interaction between stronger cash generation and continued buybacks could be an important part of the equity story. Yet behind the positive DAYBUE headlines, investors should also be aware of how any shift in Medicaid coverage terms could... Read the full narrative on Neuren Pharmaceuticals (it's free!)Neuren Pharmaceuticals' narrative projects A$166.7 million revenue and A$228.4 million earnings by 2028.Uncover how Neuren Pharmaceuticals' forecasts yield a A$23.45 fair value, a 75% upside to its current price.Exploring Other PerspectivesASX:NEU 1-Year Stock Price Chart Some of the most optimistic analysts were already assuming A$239.5 million in 2028 revenue and A$140.4 million in earnings, so this DAYBUE update might either reinforce or challenge that view depending on how you weigh faster rare disease diagnosis against concentration and pricing risks.Explore 9 other fair value estimates on Neuren Pharmaceuticals - why the stock might be worth over 5x more than the current price!Reach Your Own ConclusionDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your Neuren Pharmaceuticals research is our analysis highlighting 2 key rewards that could impact your investment decision.Our free Neuren Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Neuren Pharmaceuticals' overall financial health at a glance.No Opportunity In Neuren Pharmaceuticals?Our top stock finds are flying under the radar-for now. Get in early:Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.We've uncovered the 7 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Neuren Pharmaceuticals might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2634230366","isCrawlerRequest":true}